China Oncology Focus (COF), a subsidiary of Hong Kong-based Lee's Pharma, reported that its anti-PD-L1 antibody, socazolimab, was granted breakthrough therapy status in China . Lee's said it plans to file a China NDA for socazolimab as a cervical cancer therapy in Q2 2021. In 2014, Lee's acquired China rights to the candidate from San Diego 's Sorrento Therapeutics in a deal worth over $50 million. The two companies are currently in talks about partnering additional Sorrento antibodies. More details.... Stock Symbols: (HK: 950) (NSDQ: SRNE) Share this with colleagues: // //